Search Thermo Fisher Scientific
Element Search
Structure Search
Thermo Scientific Chemicals
Carbamazepine, 98%
Carbamazepine (Carbamazepen), CAS # 298-46-4, is an aromatic ring of the dibenzoazepine class that acts as a sodium channel blocker.
Have Questions?
Change view
Catalog number FSA344360250
View Price:Sign InSign in to see your account pricing. Need an account? Register with us today.
Quantity:
25 g
Packaging:
Glass bottle
Specifications
Chemical Name or MaterialCarbamazepine
Name Note98%
CAS298-46-4
Health Hazard 1GHS Signal Word: Danger
Health Hazard 2GHS H Statement
May cause an allergic skin reaction.
Harmful if swallowed.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
May cause an allergic skin reaction.
Harmful if swallowed.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
View more
This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
General Description
- Carbamazepine is an aromatic ring of the dibenzoazepine class that acts as a sodium channel blocker
- It is a tricyclic antidepressant-like drug that reduces post-tetanic potentiation
Applications
- Carbamazepine can be used as a sodium channel blocker and as a glutamate-transporter agonist to reduce neural activity and produce inhibitory effects in the brain
- Carbamazepine is useful in the research of pain, epilepsy, and manic depression
RUO – Research Use Only
General References:
- Ben-Menachem, E.; Grebe, H.P.; Terada, K.; Jensen, L.; Li, T.; De Backer, M.; Steiniger-Brach, B.; Gasalla, T.; Brock, M.; Biton, V. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. Epilepsia. 2019, 60(12), 2437-2447. Erratum in: Epilepsia. 2021, 62(4), 1039.
- Schmitz, B.; Dimova, S.; Zhang, Y.; Chellun, D.; De Backer, M.; Gasalla, T. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. Epilepsy Res. 2020, 159, 106220.